Showing 1-10 of about 338 articles.

MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan

LA JOLLA, Calif., Jan. 18, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

January 18, 2021

MediciNova, Inc.

MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners

LA JOLLA, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

January 11, 2021

MediciNova, Inc.

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS

LA JOLLA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

December 29, 2020

MediciNova, Inc.

MediciNova Added to the NASDAQ Biotechnology Index

LA JOLLA, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

December 15, 2020

MediciNova, Inc.

MediciNova Announces Positive Optical Coherence Tomography Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Published in Multiple Sclerosis Journal

LA JOLLA, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

November 25, 2020

MediciNova, Inc.

MediciNova Announces Initiation of Master Virus Seed Stock Production for its Intranasal COVID-19 Vaccine using BC-PIV Vector Technology

LA JOLLA, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

November 24, 2020

MediciNova, Inc.

MediciNova Announces Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience™ 2020

LA JOLLA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

November 12, 2020

MediciNova, Inc.

MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy

LA JOLLA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

October 22, 2020

MediciNova, Inc.

MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair

LA JOLLA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

October 21, 2020

MediciNova, Inc.

MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020

LA JOLLA, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

October 13, 2020

Showing 1-10 of about 338 articles.

Search Results

Organization: (MediciNova, Inc.)

MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Japan

MediciNova Enters into US$20 Million Securities Purchase Agreement with a fund managed by 3D Investment Partners

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS

MediciNova Added to the NASDAQ Biotechnology Index

MediciNova Announces Positive Optical Coherence Tomography Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Published in Multiple Sclerosis Journal

MediciNova Announces Initiation of Master Virus Seed Stock Production for its Intranasal COVID-19 Vaccine using BC-PIV Vector Technology

MediciNova Announces Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience™ 2020

MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy

MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair

MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020

Newswire Distribution Network & Management

About Us